Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Journal of Viral Hepatitis
|
August 4, 2017
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
C Fournier, T W Hoffmann, V Morel, et al.
Journal of Clinical Microbiology
|
December 14, 2011
Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients
V Descamps, A Op de Beeck, C Plassart, et al.
The Journal of Nutrition, Health & Aging
|
January 24, 2022
Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities
J Moyet, F Helle, G Bourdenet, et al.
Journal of Viral Hepatitis
|
November 20, 2008
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
L Alvarez-Lajonchere, N H Shoukry, B Grá, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Journal of Viral Hepatitis
|
August 4, 2017
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
C Fournier, T W Hoffmann, V Morel, et al.
Journal of Clinical Microbiology
|
December 14, 2011
Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients
V Descamps, A Op de Beeck, C Plassart, et al.
The Journal of Nutrition, Health & Aging
|
January 24, 2022
Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities
J Moyet, F Helle, G Bourdenet, et al.
Journal of Viral Hepatitis
|
November 20, 2008
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
L Alvarez-Lajonchere, N H Shoukry, B Grá, et al.
Page
of 2